Tetrahydrocyclohepta Indazole Crystal Forms for Oral Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for estrogen receptor-positive breast cancer, particularly those resistant to aromatase inhibitors, face challenges due to poor pharmacokinetic properties of drugs like fulvestrant, leading to low oral bioavailability and inadequate tissue distribution, resulting in insufficient degradation of mutant estrogen receptors.
Innovation Solution
Development of specific crystal forms of tetrahydrocyclohepta indazole compounds with improved pharmacokinetic properties, including crystal forms A, B, and C, which exhibit enhanced X-ray powder diffraction patterns and thermogravimetric analysis, demonstrating better oral absorption and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fulvestrant is administered via intramuscular injection to treat AI-resistant ER-mutant breast cancer, then it can achieve some therapeutic effect, but it exhibits poor pharmacokinetic properties including near-zero oral bioavailability and high blood clearance rate
Solution Approach 1:
The patent applies parameter changes by developing novel chemical compounds with modified molecular structures (formula I and formula II) that improve oral bioavailability while maintaining or enhancing anti-tumor activity. The structural modifications include changes to the core scaffold and substituent groups, which alter pharmacokinetic parameters such as absorption, distribution, and clearance rates.
Solution Approach 2:
The patent employs composite materials by creating salt forms of the developed compounds (e.g., hydrochloride salts, sulfate salts, mesylate salts) to improve solubility, stability, and oral bioavailability. These salt forms combine the active pharmaceutical ingredient with suitable counterions to achieve optimal pharmacokinetic properties for oral administration.
2Reliability
If fulvestrant is administered through intramuscular injection, then it can treat breast cancer, but it faces significant issues in tissue distribution due to its highly lipophilic structure
Solution Approach 1:
The patent modifies the lipophilicity parameter of the drug molecule by adjusting the hydrophobic and hydrophilic balance in the molecular structure. This is achieved by modifying the core scaffold and substituent groups to reduce excessive lipophilicity while maintaining target binding affinity, thereby improving tissue distribution characteristics.
Solution Approach 2:
The patent applies local quality by introducing polar functional groups or modifying specific regions of the molecule to improve local solubility and distribution properties in aqueous environments, while maintaining the hydrophobic regions necessary for membrane permeability and target binding.
3Ease of operation
If the currently approved dose of fulvestrant is used, then it can be administered conveniently, but it does not achieve sufficient tissue concentrations to completely degrade ER, particularly mutant ER
Solution Approach 1:
The patent enhances the potency of the compound by modifying the molecular structure to improve binding affinity and degradation efficiency of ER, particularly mutant ER. The structural modifications enable the compound to achieve sufficient tissue concentrations at lower doses, thereby maintaining dosage convenience while improving therapeutic efficacy.
Solution Approach 2:
The patent creates analogs and derivatives of the core structure that replicate and enhance the ER degradation function. By developing multiple compounds with similar core structures but different substituent patterns, the patent identifies optimized versions that achieve superior ER degradation at lower doses.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These crystal forms show superior efficacy against both wild-type and mutant ESR1-positive tumors, offering more effective treatment options for ER+/HER2− breast cancer by achieving stable concentrations in tissues and demonstrating excellent activity in various cell types.
Implementation Method 1
wherein the crystal form A has an X-ray powder diffraction pattern comprising characteristic diffraction peaks at the following 2θ angles: 20.92±0.20°, 22.08±0.20°, and 24.70±0.20°
Data Source
AI summary
A class of salt forms and crystal forms of a tetrahydrocyclohepta indazole compound and a preparation method therefor. Specifically disclosed is the uses of the salt form and crystal form of the compound of formula (I) in the preparation of a drug for treating related diseases.